Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

1975 ◽  
Vol 211 (1) ◽  
pp. 1-9 ◽  
Author(s):  
U. K. Rinne ◽  
E. Birket-Smith ◽  
E. Dupont ◽  
E. Hansen ◽  
M. Hyyppä ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Decarboxylase Inhibitor

Dopamine agonists for parkinson’s disease

1991 ◽  
Vol 29 (2) ◽  
pp. 7-8
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Therapeutic Efficacy ◽  
Dopamine Agonists ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor ◽  
Duration Of Action ◽  
Motor Disability ◽  
The Uk

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.

scholarly journals The drug treatment of parkinson’s disease

1984 ◽  
Vol 22 (10) ◽  
pp. 37-40
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Drug Treatment ◽  
Dopamine Agonist ◽  
Monoamine Oxidase B ◽  
Anticholinergic Drugs ◽  
Decarboxylase Inhibitor ◽  
Progressive Degeneration ◽  
The Brain

The symptoms of idiopathic Parkinson’s disease are due mainly to progressive degeneration of the dopaminergic nigro-striatal pathways in the brain. The drugs which can help fall into five categories: dopamine replacement, using dopa with a decarboxylase inhibitor; a dopamine agonist, bromocriptine;1 selegiline, recently introduced, which inhibits monoamine oxidase B; anticholinergic drugs; and amantadine.2 This article discusses recent ideas about the management of Parkinson’s disease, particularly about levodopa dosage, bromocriptine and selegiline.

Small doses of levodopa for parkinson’s disease

1990 ◽  
Vol 28 (14) ◽  
pp. 55-56
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Effective Dose ◽  
Low Dose ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor ◽  
Minimum Effective Dose ◽  
Small Doses ◽  
Full Discussion ◽  
Low Strength

Our last full discussion of Parkinson’s disease recommended using the minimum effective dose of levodopa in combination with a peripheral dopa decarboxylase inhibitor1 - carbidopa in Sinemet (co-careldopa) and benserazide in Madopar (co-beneldopa). Combined formulations offer levodopa in various doses together with an inhibitor: Madopar 62.5 contains levodopa 50mg + benserazide 12.5mg base; low strength Sinemet, Sinemet-LS, contains levodopa 50mg + carbidopa 12.5mg. Both these preparations offer a relatively low dose but the Sinemet-LS tablet is scored and the 62.5mg tablet of Madopar Dispersible can be broken so that even lower doses can be used. This article examines when these small doses are useful.

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease

Neurology ◽  
1975 ◽  
Vol 25 (10) ◽  
pp. 911-911 ◽  
Author(s):  
A. LIEBERMAN ◽  
A. GOODGOLD ◽  
S. JONAS ◽  
M. LEIBOWITZ
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor

Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitor

1972 ◽  
Vol 202 (1) ◽  
pp. 1-20 ◽  
Author(s):  
U. K. Rinne ◽  
V. Sonninen ◽  
T. Siirtola
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Decarboxylase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document